title: Classification of anaphylaxis and utility of the EAACI Taskforce position paper on anaphylaxis in children.
abstract: Correct management and classification of anaphylaxis is mandatory. Records of emergency department (ED) visits to any of the three pediatric hospitals in Stockholm, because of reactions to foods during 2007, were identified. A retrospective analysis of clinical ED records of 371 children with 381 unique occasions of reactions to foods was performed. Symptoms/signs of reactions to foods recorded for classification of anaphylaxis were related to those presented in the EAACI Taskforce position paper on Anaphylaxis in Children (Allergy 2007; 62: 857). Forty-six different symptoms/signs of reactions to foods were retrieved. Several severe signs or symptoms from the respiratory tract and signs indicating reduced brain perfusion were not described in detail in the EAACI paper, hampering correct classification of anaphylaxis including grading of severity in our material. After modification of the EAACI classification including such signs and symptoms, we were able to classify 128 (35%) children with anaphylaxis. Seventy children (19%) did not fulfill our modified EAACI's criteria for anaphylaxis. They had been given adrenaline before or at arrival to hospital, possibly preventing anaphylaxis. Another 173 (47%) children/adolescents had neither been given adrenalin, nor fulfilled the criteria for anaphylaxis. Classification of food-induced anaphylaxis and severity grading should be built on signs and symptoms to facilitate diagnosis. The existing EAACI tool is helpful, but for Swedish children it is not quite applicable, in particular because of the lack of description of some respiratory, neurological or possible cardiovascular signs and symptoms.
authors.affiliation: Department of Paediatrics, Sachs' Children's Hospital, Södersjukhuset, Stockholm, Sweden. mirja.vetander@ki.se
authors.forename: Mirja
authors.initials: M
authors.lastname: Vetander
authors.forename: Daiva
authors.initials: D
authors.lastname: Helander
authors.forename: Charlotta
authors.initials: C
authors.lastname: Lindquist
authors.forename: Gunilla
authors.initials: G
authors.lastname: Hedlin
authors.forename: Tobias
authors.initials: T
authors.lastname: Alfvén
authors.forename: Eva
authors.initials: E
authors.lastname: Ostblom
authors.forename: Caroline
authors.initials: C
authors.lastname: Nilsson
authors.forename: Gunnar
authors.initials: G
authors.lastname: Lilja
authors.forename: Magnus
authors.initials: M
authors.lastname: Wickman
mesh_terms: D000707:Anaphylaxis / Q000145:classification; D001921:Brain / Q000473:pathology; D002648:Child; D018450:Disease Progression; D004837:Epinephrine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000145:classification / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D007256:Information Systems; D038801:International Classification of Diseases; D008297:Male; D012137:Respiratory System / Q000473:pathology*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D012867:Skin / Q000473:pathology
chemical_list: D004837:Epinephrine